Nalazite se na CroRIS probnoj okolini. Ovdje evidentirani podaci neće biti pohranjeni u Informacijskom sustavu znanosti RH. Ako je ovo greška, CroRIS produkcijskoj okolini moguće je pristupi putem poveznice www.croris.hr
izvor podataka: crosbi !

Design of recombinant viral vaccines based on mumps virus (CROSBI ID 723948)

Prilog sa skupa u zborniku | sažetak izlaganja sa skupa | međunarodna recenzija

Pali, Dorotea ; Košutić Gulija, Tanja ; Slović, Anamarija ; Ivančić Jelečki, Jelena ; Forčić, Dubravko Design of recombinant viral vaccines based on mumps virus. 2021

Podaci o odgovornosti

Pali, Dorotea ; Košutić Gulija, Tanja ; Slović, Anamarija ; Ivančić Jelečki, Jelena ; Forčić, Dubravko

engleski

Design of recombinant viral vaccines based on mumps virus

Recombinant viral vectors are particularly interesting for the development of vaccines against emerging viral diseases. So far, only few studies have shown the potential of mumps virus (Mumps orthorubulavirus, family Paramyxoviridae) to be used as a recombinant vector. The objective of this research is to develop recombinant vaccines for hepatitis C virus (HCV) and human respiratory syncytial virus (RSV) based on mumps recombinant virus (vMRV2). Virus vMRV2 was generated using a reverse genetics technology (rescue) and has a genome sequence based on the consensus of vaccine strain L-Zagreb. The rescue method we use comprises a co- transfection of BSRT7 cells with three expression plasmids that encode nucleocapsid protein and components of viral RNA-dependant RNA polymerase, and a plasmid with full-length virus genome (pMRV2). Additional transcription units were added to pMRV2 in order to produce recombinant live attenuated vaccines for HCV or RSV. Sequences encoding ectodomains of RSV F protein and HCV E1 and E2 proteins were cloned into the pMRV2 with or without the addition of transmembrane and cytoplasmic domain (TMD/CD) of mumps F protein. We expect that RSV and HCV genes will be expressed in infected cells ; proteins with the addition of TMD/CD of mumps F protein will be incorporated in viral particles as well. We have produced recombinant viruses vMRV2, vF RSV-MRV2 (vector vaccine for RSV) and vE1E2TMD HCV-MRV2 (vector vaccine 1 for HCV) ; rescue for vCE1E2 HCV-MRV2 (vector vaccine 2 for HCV) is currently in progress. Viral genetic stability was analysed by next generation sequencing after passaging of vF RSV-MRV2 in Vero cells, a putative production cell line. The biological significance of subconsensus population variability, as well as nucleotide changes observed on the level of viral population consensus, is being analyzed, as minor variant of virus quasispecies can affect the attenuation status of live viral vaccines.

design of recombinant vaccines, mumps virus

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

Podaci o prilogu

2021.

objavljeno

Podaci o matičnoj publikaciji

Podaci o skupu

15th Vaccine Congress

predavanje

03.10.2021-06.10.2021

online

Povezanost rada

nije evidentirano